Search people, articles, bills, and more
Brain tumors affect over a million Americans, and for many types, survival rates have not improved significantly in decades. This bill matters because it directly addresses the urgent need for more effective treatments and better patient care by focusing on key areas: boosting research, improving information sharing among scientists, and supporting patients through awareness and better long-term care.
If this bill becomes law, it could accelerate the development of new therapies, particularly for aggressive brain cancers like glioblastoma, and make it easier for patients to find and participate in clinical trials. It also aims to improve the quality of life for survivors by developing specialized care programs. Without this bill, research efforts might remain fragmented, access to biospecimens could continue to be a challenge for researchers, and patients might miss out on potential life-saving treatments due to a lack of awareness or difficulty navigating the clinical trial landscape.
No reactions yet. Be the first to weigh in.
Brain tumors affect over a million Americans, and for many types, survival rates have not improved significantly in decades. This bill matters because it directly addresses the urgent need for more effective treatments and better patient care by focusing on key areas: boosting research, improving information sharing among scientists, and supporting patients through awareness and better long-term care.
If this bill becomes law, it could accelerate the development of new therapies, particularly for aggressive brain cancers like glioblastoma, and make it easier for patients to find and participate in clinical trials. It also aims to improve the quality of life for survivors by developing specialized care programs. Without this bill, research efforts might remain fragmented, access to biospecimens could continue to be a challenge for researchers, and patients might miss out on potential life-saving treatments due to a lack of awareness or difficulty navigating the clinical trial landscape.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
| AMOUNT | PROGRAM | TYPE | YEARS |
|---|---|---|---|
| $50,000,000 | Glioblastoma Therapeutics Network | discretionary | fiscal years 2026 through 2030 |
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
| TYPE | AMOUNT | WHO |
|---|---|---|
| administrative | Withholding funding | Individuals or entities that commit repeated or egregious violations of biospecimen reporting requirements |